Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C21 in hospitalised COVID-19 patients not requiring mechanical ventilation
2020-001502-38Phase 2Completed
- Sponsor
- Vicore Pharma
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and airway morbidity comparing C21 with Placebo (2 arms). Primary endpoint: Change from baseline in C-reactive protein (CRP). Started Apr 2020; status: completed.
02
Drugs
buloxibutid
03
Conditions
coronavirus disease 2019 (COVID-19)airway morbidity
Beyond the preview
Go deeper on 2020-001502-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001502-38.